Establishment and Development of the First Biobank of Inflammatory Bowel Disease, Suspected to Primary Immunodeficiency Diseases in Iran

Sherkat, Roya; Rostami, Soodabeh; Yaran, Majid; Emami, Mohammad Hassan; Saneian, Hosein; Tavakoli, Hamid; Adibi, Peyman; Behnam, Mahdieh; Sheykhbahaei, Saba; Bagherpour, Bahram; Khoshnevisan, Razieh; Najafi, Somayeh

Establishment and Development of the First Biobank of Inflammatory Bowel Disease, Suspected to Primary Immunodeficiency Diseases in Iran

Document Type : Original Article

Authors

¹ Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

² Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

³ Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Poursina Hakim Research Institute, Isfahan, Iran

⁵ Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran

⁶ Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

⁷ Medical Genetics Laboratory, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Inflammatory bowel disease (IBD) might be an immunodeficiency rather than an excessive inflammatory reaction. IBD, suspected to primary immunodeficiency diseases biobank (IBDSPIDB) as a resource for researches can help improve the prevention, diagnosis, and illness treatment and the health promotion throughout the society. Therefore, we launched the biobank of IBDSPID for the first time in Iran. Materials and Methods: This study was designed to provide the IBDSPIDB to have a high-quality DNA, RNA, and cDNA. Among of 365 patients, 39 have inclusion criteria that were as below: (1) IBD diagnosis before 5 years of age. (2) Resistance to conventional therapy of IBD. (3) Severe IBD. (4) Signs of SPID (including ear infections or pneumonia or recurrent sinus within the 1-year period; failure to thrive; poor response to the prolonged use of antibiotics; persistent thrush or skin abscesses; or a family history of PID). Results: Out of 39 patients, 51.3% were males. The mean age was 32.92 ± 15.90 years old. Ulcerative colitis (79.5%) was more than Crohn's disease. The majority of patients (50.0%) had severe IBDSPID. Resistance to drugs and consanguinity was 12.9% and 47.4%, respectively. Age at onset in 65.8% of patients was after 17 years old. Patients with autoimmune, allergy, and immunodeficiency disease history were 33.3%, 33.3%, and 10.36%, respectively. RNA and cDNA yields large quantities of high-quality DNA obtained and stored. Conclusion: Our biobank would be valuable for future genetic and molecular study to be more about the relation between IBD and PID

Keywords

References

1.	Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78. [PUBMED]
2.	Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
3.	Fiocchi C. Inflammatory bowel disease pathogenesis: Where are we? J Gastroenterol Hepatol 2015;30 Suppl 1:12-8.
4.	Malys MK, Campbell L, Malys N. Symbiotic and antibiotic interactions between gut commensal microbiota and host immune system. Medicina (Kaunas) 2015;51:69-75.
5.	Glocker E, Grimbacher B. Inflammatory bowel disease: Is it a primary immunodeficiency? Cell Mol Life Sci 2012;69:41-8.
6.	Fujimoto T, Kato J, Nasu J, Kuriyama M, Okada H, Yamamoto H, et al. Change of clinical characteristics of ulcerative colitis in Japan: Analysis of 844 hospital-based patients from 1981 to 2000. Eur J Gastroenterol Hepatol 2007;19:229-35.
7.	Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011;140:1785-94.
8.	Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: A review of 457 cases. J Gastroenterol Hepatol 2005;20:1691-5.
9.	Vahedi H, Merat S, Momtahen S, Olfati G, Kazzazi AS, Tabrizian T, et al. Epidemiologic characteristics of 500 patients with inflammatory bowel disease in Iran studied from 2004 through 2007. Arch Iran Med 2009;12:454-60.
10.	Trauth JM, Musa D, Siminoff L, Jewell IK, Ricci E. Public attitudes regarding willingness to participate in medical research studies. J Health Soc Policy 2000;12:23-43.
11.	McCusker C, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol 2011;7 Suppl 1:S11.
12.	de Montgolfier S, Moutel G, Duchange N, Theodorou I, Hervé C, Leport C; APROCO Study Group. Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients. Pharmacogenetics 2002;12:667-75.
13.	Rohr J, Pannicke U, Döring M, Schmitt-Graeff A, Wiech E, Busch A, et al. Chronic inflammatory bowel disease as key manifestation of atypical ARTEMIS deficiency. J Clin Immunol 2010;30:314-20.
14.	Salzer E, Kansu A, Sic H, Májek P, Ikinciogullari A, Dogu FE, et al. Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. J Allergy Clin Immunol 2014;133:1651-9.e12.
15.	Denson LA, Long MD, McGovern DP, Kugathasan S, Wu GD, Young VB, et al. Challenges in IBD research: Update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis 2013;19:677-82.
16.	Mota-Vieira L, Pacheco PR, Almeida ML, Cabral R, Carvalho J, Branco CC, et al. Human DNA bank in Sao Miguel Island (Azores): A resource for genetic diversity studies. Int Congr Ser 2006;1288:388-90.
17.	García-Merino I, de Las Cuevas N, Jiménez JL, Gallego J, Gómez C, Prieto C, et al. The Spanish HIV BioBank: A model of cooperative HIV research. Retrovirology 2009;6:27.
18.	Isaian A, Moin M, Pourpak Z, Rezaei N, Aghamohammadi A, Movahedi M, et al. DNA banking of primary immunodeficiency disorders in Iran. Iran J Allergy Asthma Immunol 2006;5:201-2.

Advanced Biomedical Research